Frontline venetoclax plus low-dose cytarabine supported for older patients with AML

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Jun 14 / Springer Healthcare

Frontline venetoclax plus low-dose cytarabine supported for older patients with AML

The Alfred Hospital, Melbourne, Victoria, Australia

Haematology EHA-2020

Description

Andrew Wei presents updated findings from the phase 3 VIALE-C acute myeloid leukaemia trial, discussing how these and the VIALE-A data cement the role of venetoclax as a first-line option for older patients and those ineligible for intensive chemotherapy.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.